Alpha Cognition Secures European Patent for ZUNVEYL in Alzheimer’s Treatment
Event summary
- Alpha Cognition received a European patent for a crystalline form of benzgalantamine, the active ingredient in ZUNVEYL, for treating mild-to-moderate Alzheimer’s disease.
- The patent covers pharmaceutical compositions, manufacturing methods, and medical-use claims, extending potential protection until 2042.
- The patent can be validated across key European markets, including EU and non-EU jurisdictions like Switzerland and the UK.
- ZUNVEYL is FDA-approved as a new-generation acetylcholinesterase inhibitor with minimal gastrointestinal side effects.
The big picture
This patent grant strengthens Alpha Cognition’s global IP portfolio, supporting its strategy to position ZUNVEYL as a differentiated treatment for mild-to-moderate Alzheimer’s. The move aligns with broader industry trends toward securing robust intellectual property in key markets to fend off competitors and ensure long-term revenue streams.
What we're watching
- IP Strategy Execution
- How Alpha Cognition will leverage this patent to strengthen its market position in Europe and sustain long-term commercial potential for ZUNVEYL.
- Regulatory Validation
- Whether the European patent can be successfully validated across all targeted jurisdictions, ensuring broad IP protection.
- Competitive Differentiation
- The pace at which Alpha Cognition can differentiate ZUNVEYL from existing treatments like donepezil and rivastigmine in the Alzheimer’s market.